StockNews.com upgraded shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning. A number of other equities research analysts ...

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan ...

Hepatitis can damage your liver for years without symptoms. Learn how these viruses spread—and what truly protects your liver ...

This study provides compelling real-world evidence that statin use may significantly reduce the risk of both liver cancer and ...

Tony Summers, whose son died from HIV and Hepatitis C, fears he will be dead before his compensation is paid.

While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

Arbutus is also exiting its corporate headquarters in Pennsylvania and will terminate all in-house scientific research. The ...

The restructuring is only the latest round of layoffs to hit Arbutus after the company shed 40% of its staff and cut back on ...

Mrs Tinubu referenced data from the Federal Ministry of Health and Social Welfare, which revealed that in 2024, over 100,000 children and nearly two million adults were living with HIV.Nigeria's First ...

Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication ...